摘要
目的探讨口服西替利嗪联合雷公藤多苷治疗甲状腺相关性眼病(TAO)的疗效。方法将TAO患者48例随机分为两组,均24例。Ⅰ组给予强的松20 mg,3次/d,连续服用4周后,逐渐减量(每2周减10 mg)。Ⅱ组给予口服西替利嗪10 mg,每晚1次;雷公藤多苷10 mg,3次/d。两组均连续服用12周,比较两组的有效率及治疗前后眼球突出度、临床活动度(CAS)评分变化。结果Ⅰ组有效率与Ⅱ组效果接近,分别为54.17%和50.00%;两组治疗前后眼球突出度值与CAS评分值均有显著性差异(P<0.05)。观察期未发现明显的不良反应。结论口服西替利嗪和雷公藤多苷是治疗TAO的一种安全有效的方法。
Objective To explore the effect of oral cetirizine combined with tripterygium glycosideson for treating thyroid associated oph- thalmopathy（TAO）. Methods 48 patients （90 eyes） with TAO were randomly divided into two groups,24 cases in each group. The group I was treated with oral prednisone 20 rag,three times per day for successive 4 weeks,then the dose was gradually decreased by 10 mg per 2 weeks,with the total therapy period of 12 weeks. The group group ]l was given with oral cetirizin 10 rag,once per night, and tripterygium glycosideson 10 mg,three times per day for 12 weeks. The effective rate,the scoring change of proptosis degree before and after treatment and clinical activity score（CAS） in the two groups were recorded and compared between the two groups. Results The effective rate in the group I and the group II was similar, which was 54. 17% and 50.00% respectively. The proptosis degrees of and the CAS scores in the two groups both had significant difference between pretreatment and posttreatment（P〈0.05）. No obvious side effects were found in the two groups. Conclusion Oral cetirizine and tripterygium glyeosideson is a safe and effective therapy method for treating TAO.
出处
《中国药业》
CAS
2012年第18期85-86,共2页
China Pharmaceuticals
关键词
西替利嗪
雷公藤多苷
甲状腺相关性眼病
cetirizine
tripterygium glycosides
thyroid associated ophthalmopathy
